InnoCare's Orelabrutinib Combination Shows 100% Response Rate in Preliminary Phase 2 MZL Results
InnoCare Pharma presented three orelabrutinib studies at the Japanese Society of Hematology meeting, held Oct. 9-11, 2026, in Kyoto. A Phase 2 chemotherapy-free combination showed high response rates in elderly, frail patients receiving initial treatment for diffuse large B-cell lymphoma. Preliminary Phase 2 results sh